Investor's Champion
How to make your money go further

IS Pharma plc (AIM: ISPH), results marginally miss estimates but no big deal in the grand scheme

02/06/2010 · IS Pharma (ISPH) 
The company, which provides specialist pharmaceuticals and equipment in core areas such as Oncology and Neurology saw revenue up 17% to £14.2m (2009: £12.2m).
This includes £0.7m from the Volplex and Isoplex Distribution and Sale agreement. Product sales were up 19% to £13.4m (2009: £11.2m) and pre-tax profit up 30% to £2.6m (2009: £2.0m) post exceptional items of £0.4m (2009: £0.6m). Basic earnings per share were 7.3p (2009: 9.1p). Consensus estimates were for pre-tax profit of £2.98m and eps of 8.23p, however, there was a big spread between the 2 analysts covering this one (6.7p to 9.6p!).  Cash generated from operations was up 24% to £3.1m (2009: £2.5) and cash balances at the year end were £4.2m (2009: £6.0m). During the year the Group…

Sign up and read the full article

Register to continue reading our content.

Get FREE access now

Already a member? Login